Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ginkgo Bioworks Holdings (DNA)
NYSE:DNA
Ginkgo Bioworks Holdings (DNA) Stock Price & Analysis
1,772 Followers
DNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.74 - $2.55
Previous Close$0.96
Volume54.56M
Average Volume (3M)30.35M
Market Cap
$2.10B
Enterprise Value$1.38B
Total Cash (Recent Filing)$944.07M
Total Debt (Recent Filing)$221.84M
Price to Earnings (P/E)-2.1
Beta2.79
Next Earnings
May 09, 2024EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding2,152,395,786
10 Day Avg. Volume62,930,803
30 Day Avg. Volume30,346,965
Standard Deviation0.21
R-Squared0.17
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)2.12
Price to Sales (P/S)6.27
Price to Cash Flow (P/CF)-8.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.49
Enterprise Value/Gross Profit6.74
Enterprise Value/Ebitda-2.03
Forecast
1Y Price Target
$2.03Price Target Upside112.57% Upside
Rating ConsensusHold
Number of Analyst Covering4
Ginkgo Bioworks Holdings News
Bulls Say, Bears Say
Bulls Say
Financial OutlookGinkgo expects a significant increase in total revenue for 2024, driven by strong performance in Cell Engineering revenue fueled by biopharma and government contracts.
Product DevelopmentGinkgo highlighted a broad range of projects underway with many of its users, showing versatility in its genomic and automation capabilities.
Strategic PartnershipsGinkgo's expanded alliance with Novo Nordisk is expected to enhance manufacturing of therapeutics for chronic diseases, highlighting the company's growing collaborations.
Bears Say
Earnings4Q EPS of ($0.11) also came in below Visible Alpha consensus of ($0.08) and GSe of ($0.06).
Financial Performance4Q revenue of $34.8mn was below Visible Alpha consensus of $39.6mn and GSe of $41.0mn.
GuidanceDNA fell short of new cell program guidance in 2023 and provided guidance for 100-120 new programs in 2024, which is viewed as ambitious.
---
Ownership Overview
8.76% Insiders
11.53% Mutual Funds
53.28% Other Institutional Investors
26.42% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DNA FAQ
What was Ginkgo Bioworks Holdings’s price range in the past 12 months?
Ginkgo Bioworks Holdings lowest stock price was $0.74 and its highest was $2.54 in the past 12 months.
What is Ginkgo Bioworks Holdings’s market cap?
Currently, no data Available
When is Ginkgo Bioworks Holdings’s upcoming earnings report date?
Ginkgo Bioworks Holdings’s upcoming earnings report date is May 09, 2024 which is tomorrow.
How were Ginkgo Bioworks Holdings’s earnings last quarter?
Ginkgo Bioworks Holdings released its earnings results on Feb 29, 2024. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.097 by -$0.013.
Is Ginkgo Bioworks Holdings overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings pay dividends?
Ginkgo Bioworks Holdings does not currently pay dividends.
What is Ginkgo Bioworks Holdings’s EPS estimate?
Ginkgo Bioworks Holdings’s EPS estimate is -$0.08.
How many shares outstanding does Ginkgo Bioworks Holdings have?
Ginkgo Bioworks Holdings has 1,700,266,500 shares outstanding.
What happened to Ginkgo Bioworks Holdings’s price movement after its last earnings report?
Ginkgo Bioworks Holdings reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.097. Following the earnings report the stock price went down -15.132%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings?
Among the largest hedge funds holding Ginkgo Bioworks Holdings’s share is ARK Investment Management LLC. It holds Ginkgo Bioworks Holdings’s shares valued at 336M.
---
Ginkgo Bioworks Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.03 (112.57% Upside)
$2.03 (112.57% Upside)
Blogger Sentiment
Bullish
DNA Sentiment 64%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 16.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.95%
12-Months-Change
Fundamentals
Return on Equity
-63.02%
Trailing 12-Months
Asset Growth
-34.42%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings (NYSE:DNA) is a biotechnology company that offers a platform for cell programming that enables the biological production of various products across the food, pharmaceutical, and fragrance industry. Its platform provides equipment, software, robotic automation, and tools to support genetic engineering, analytics, and fermentation.
---
DNA Company Deck
---
DNA Earnings Call
Q4 2024
0:00 / 0:00
---
DNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
---
DNA Stock 12 Months Forecast
Average Price Target
$2.03
▲(112.57% Upside)
Technical Analysis
Best Analysts Covering DNA
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-31.45%
reiterated a buy rating 8 months ago
Copying Gaurav Goparaju's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -31.45% per trade.
---